Haesook Teresa Kim

Splenic irradiation prior to allogeneic hematopoietic cell transplantation for patients with myelofibrosis.

Bales JR, Kim HT, Portillo R, Patel C, McAfee S, Dey B, Spitzer T, Chen YB, El-Jawahri A, DeFilipp Z, Hobbs GS.

Bone Marrow Transplant. 2023 Jan 10. PMID: 36624162

Lower Incidence of Chronic GVHD Observed after Transplantation with Cryopreserved Unrelated Allogeneic Stem Cells.

Maurer K, Kim HT, Garrity HM, Liney D, Cutler CS, Antin JH, Koreth J, Ritz J, Shapiro RM, Romee R, Ho VT, Gooptu M, Soiffer RJ, Wu CJ, Nikiforow S.

Blood Adv. 2023 Jan 03. PMID: 36595453

Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials.

DeFilipp Z, Kim HT, Yang Z, Noonan J, Blazar BR, Lee SJ, Pavletic SZ, Cutler C.

Blood Adv. 2022 12 27. 6(24):6263-6270. PMID: 36083121

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.

Fathi AT, Kim HT, Soiffer RJ, Levis MJ, Li S, Kim AS, Mims AS, DeFilipp Z, El-Jawahri A, McAfee SL, Brunner AM, Narayan R, Knight LW, Kelley D, Bottoms AS, Perry LH, Wahl JL, Brock J, Breton E, Ho VT, Chen YB.

Blood Adv. 2022 11 22. 6(22):5857-5865. PMID: 36150050

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.

Whangbo JS, Nikiforow S, Kim HT, Wahl J, Reynolds CG, Rai SC, Kim S, Burden A, Alho AC, Lacerda JF, Alyea EP, Cutler CS, Ho VT, Antin JH, Soiffer RJ, Ritz J, Koreth J.

Blood Adv. 2022 11 08. 6(21):5786-5796. PMID: 35475885

Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation.

Rambaldi B, Kim HT, Arihara Y, Asano T, Reynolds C, Manter M, Halpern M, Weber A, Koreth J, Cutler C, Gooptu M, Nikiforow S, Ho VT, Antin JH, Romee R, Ampudia J, Ng C, Connelly S, Soiffer RJ, Ritz J.

Haematologica. 2022 11 01. 107(11):2617-2629. PMID: 35484649

Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease.

Donato V, Kim HT, Stowe P, Reynolds CG, Ritz J, Koreth J, Whangbo JS.

Front Immunol. 2022. 13:954966. PMID: 36189229

Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma.

Jacobsen ED, Kim HT, Jeter E, Jacobson C, Fisher DC, Armand P.

Bone Marrow Transplant. 2022 11. 57(11):1719-1720. PMID: 35996021

Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease.

Kim HT, Koreth J, Whangbo J, Nikiforow S, Reynolds CG, Stowe P, Ho VT, Cutler C, Antin JH, Soiffer RJ, Ritz J.

Blood Adv. 2022 08 09. 6(15):4392-4402. PMID: 35617682

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML.

Murdock HM, Kim HT, Denlinger N, Vachhani P, Hambley B, Manning BS, Gier S, Cho C, Tsai HK, McCurdy S, Ho VT, Koreth J, Soiffer RJ, Ritz J, Carroll MP, Vasu S, Perales MA, Wang ES, Gondek LP, Devine S, Alyea EP, Lindsley RC, Gibson CJ.

Blood. 2022 06 16. 139(24):3546-3557. PMID: 35286378